鼠神经生长因子治疗脊髓小脑共济失调3型临床观察  

Clinical research of mouse Nerve Growth Factor on treatment of SCA3

作　　者：李琳[1] 刘扬[1] 陈坤[1] 王秋丽[1] 刘喜灿[1] 卜淑芳[1] 贾延劼[2] 

机构地区：[1]郑州大学附属郑州中心医院老年神经内科,郑州450006 [2]郑州大学第一附属医院神经内科,郑州450002

出　　处：《医药论坛杂志》2015年第6期69-70,73,共3页Journal of Medical Forum

摘　　要：目的分析鼠神经生长因子(m NGF)治疗脊髓小脑共济失调3型(SCA3)的效果。方法收集2011年6月—2014年7月郑州中心医院神经内科、郑州大学第一附属医院神经内科30例脊髓小脑共济失调3型患者随机分为治疗组15例和对照组15例,所有患者均给予维生素B族口服、改善脑循环和平衡康复等常规治疗,治疗组加用m NGF治疗,观察2组临床疗效,采用世界神经病联合会国际合作共济失调量表(ICARS)及日常生活能力量表(ADL)进行疗效评定。结果治疗组的总有效率为86.67%高于对照组的53.33%,差异有统计学意义(P<0.05);治疗后2组ICARS评分和ADL评分差异有统计学意义(P<0.01)。结论 m NGF应用于脊髓小脑共济失调3型患者可减少患者周围神经损伤,促进患者平衡功能恢复。Objective To analyze the efficacy of mouse nerve growth factor（mNGF） in spinocerebellar ataxia type 3. Methods Totally 30 patients with spinocerebellar ataxia type 3 who were treated in our hospital and the first hospital of Zhengzhou University from June ,2011 to July ,2014 they were randomly diveded into treatment group and control group. All patients were given vitamin B orally and balance rehabilitaion. Treatment group added with mNGF. Compared the clinical efficacy of 2groups. The efficacy was assessed by International Cooperative Ataxia Rating Scale （ICARS） and Activity of Daily Living Scale （ADL）. Results The total efficiency of treatment group（ 86. 67% ） was higher than that of control group（ 53.33% ） , the difference was statistically significant（ P 〈0. 05） . The level of ICARS and ADL of 2groups after treatment were higher than that before treatment, difference was statistically significant（ P 〈 0. 01 ） . Conclusion mNGF can effectively reduce the peripheral nerve injury in patients with spinocerebellar ataxia type 3, and promote the recovery of balance function.

关 键 词：鼠神经生长因子 脊髓小脑共济失调 临床观察 

分 类 号：R743[医药卫生—神经病学与精神病学]